

Instruction Manual

pGeneBLAzer[™] TOPO[®] TA Expression Kits

For five-minute cloning of *Taq* polymeraseamplified PCR products into a vector for promoter function analysis in mammalian cells using the β -lactamase reporter gene

Catalog nos. 12578-019 and 12578-027

Version B 27 January 2004 *25-0660*

A Limited Use Label License covers this product (see Purchaser Notification). By use of this product, you accept the terms and conditions of the Limited Use Label License.

Table of Contents

Table of Contents	iii
TOPO [®] Cloning Procedure for Experienced Users	v
Kit Contents and Storage	vii
Accessory Products	x
Introduction	1
Overview	1
How TOPO [®] Cloning Works	2
The GeneBLAzer [™] Technology	3
Experimental Outline	4
Methods	5
General Cloning Considerations	5
Producing PCR Products	7
Setting Up the TOPO [®] Cloning Reaction	8
Transforming One Shot [®] TOP10 Competent Cells	
Analyzing Transformants	
Optimizing the TOPO [®] Cloning Reaction	
Transfecting Cells	
Creating Stable Cell Lines	
Detecting β -Lactamase Reporter Activity	
Appendix	20
Performing the Control Reactions	
Gel Purifying PCR Products	
Adding 3' A-Overhangs Post-Amplification	
Map and Features of pGeneBLAzer-TOPO [®]	
Map of pGeneBLAzer™/UbC	
Recipes	
Technical Service	
Purchaser Notification	
Product Qualification	
References	

TOPO[®] Cloning Procedure for Experienced Users

Introduction This quick reference sheet is provided for experienced users of the TOPO[®] Cloning procedure. If you are performing the TOPO[®] Cloning procedure for the first time, we recommend that you follow the detailed protocols provided in the manual.

Step			Action
Produce the PCR product			r sequence of interest using <i>Taq</i> polymerase and d the PCR reaction with a final 7 to 10 minute
	2.	Use agarose gel electro PCR product.	phoresis to check the integrity and yield of your
Perform the TOPO [®]	1.	Set up the following TO	DPO [®] Cloning reaction.
Cloning Reaction		Note: If you plan to trans the TOPO [®] Cloning react	form electrocompetent <i>E. coli</i> , use Dilute Salt Solution in on.
		Fresh PCR product	0.5 to 4 µl
		Salt Solution	1 µl
		Sterile water ad	d to a final volume of 5 μl
		TOPO [®] vector	<u> </u>
		Total volume	6 μl
	2.	Mix gently and incubat	e for 5 minutes at room temperature.
	3.	Place on ice and procee competent <i>E. coli</i> , below	d to transform One Shot [®] TOP10 chemically v.
Transform One Shot [®] TOP10 Chemically	1.	Add 2 μl of the TOPO [®] chemically competent	Cloning reaction into a vial of One Shot [®] TOP10 <i>E. coli</i> and mix gently.
Competent E. coli	2.	Incubate on ice for 5 to	30 minutes.
	3.	Heat-shock the cells for Immediately transfer th	: 30 seconds at 42°C without shaking. ne tube to ice.
	4.	Add 250 µl of room ten	perature S.O.C. Medium.
	5.	Incubate at 37°C for 1 h	our with shaking.
	6.	1 .	terial culture on a prewarmed LB agar plate Impicillin and incubate overnight at 37°C.

Control Reaction

We recommend using the Control PCR Template and the Control PCR Primers included with the kit to perform the control reaction. See pages 20-21 for instructions.

Kit Contents and Storage

Types of Kits This manual is supplied with the following products.

Note: Each kit is also supplied with an appropriate GeneBLAzerTM Detection Kit and the GeneBLAzerTM Detection Kit manual.

Kit	Reactions	Catalog no.
pGeneBLAzer [™] TOPO [®] TA Expression Kit for <i>In Vitro</i> Detection	20	12578-019
pGeneBLAzer [™] TOPO [®] TA Expression Kit for In Vivo Detection	20	12578-027

Kit Components The pGeneBLAzer[™] TOPO[®] TA Expression Kits include the following components. For a detailed description of the contents of each component, see pages viii-ix.

Component	Catalog no.	
	<u>12578-019</u>	<u>12578-027</u>
pGeneBLAzer [™] TOPO [®] Reagents	\checkmark	\checkmark
One Shot® TOP10 Chemically Competent E. coli	\checkmark	\checkmark
GeneBLAzer [™] In Vitro Detection Kit	\checkmark	
GeneBLAzer [™] In Vivo Detection Kit		\checkmark

Shipping andEach pGeneBLAzer™ TOPO® TA Expression Kit is shipped as described in the
table below, and contains the following boxes. Note that each kit contains Box 3a
or 3b, as appropriate. Upon receipt, store the boxes as detailed below.

Box	Item	Shipping	Storage
1	pGeneBLAzer [™] TOPO [®] Reagents	Dry ice	-20°C
2	One Shot [®] TOP10 Chemically Competent <i>E. coli</i>	Dry ice	-80°C
3a	GeneBLAzer [™] In Vitro Detection Kit	Dry ice	CCF2-FA: -20°C, dessicated and protected from light
3b	GeneBLAzer [™] In Vivo Detection Kit	Room temperature	CCF2-AM: -20°C, dessicated and protected from light
			Solutions: Room temperature, protected from light

Kit Contents and Storage, continued

pGeneBLAzer[™] TOPO[®] Reagents

The pGeneBLAzerTM TOPO[®] reagents (Box 1) are listed below. Note that the user must supply *Taq* polymerase. Store Box 1 at -20°C.

Item	Concentration	Amount
pGeneBLAzer-TOPO [®] vector,	10 ng/ μ l plasmid DNA in:	20 µl
linearized and TOPO®-adapted	50% glycerol	
	50 mM Tris-HCl, pH 7.4 (at 25°C)	
	1 mM EDTA	
	2 mM DTT	
	0.1% Triton X-100	
	100 μg/ml BSA	
	30 μM phenol red	
10X PCR Buffer	100 mM Tris-HCl, pH 8.3 (at 42°C)	100 µl
	500 mM KCl	
	25 mM MgCl ₂	
	0.01% gelatin	
dNTP Mix	12.5 mM dATP	10 µl
	12.5 mM dCTP	
	12.5 mM dGTP	
	12.5 mM dTTP	
	neutralized at pH 8.0 in water	
Salt Solution	1.2 M NaCl	50 µl
	0.06 M MgCl ₂	
Sterile Water		1 ml
T7 Sequencing Primer	0.1 μg/μl in TE Buffer, pH 8	20 µl
Control PCR Template	0.05 μg/μl in TE Buffer, pH 8	10 µl
Control PCR Primers	0.1 μg/μl each in TE Buffer, pH 8	10 µl
pGeneBLAzer [™] /UbC expression control plasmid	0.5 μg/μl in TE Buffer, pH 8	10 µl

Kit Contents and Storage, continued

One Shot[®] TOP10 Reagents

The table below describes the reagents included in the One Shot[®] TOP10 Chemically Competent *E. coli* kit (Box 2). Transformation efficiency is $\geq 1 \times 10^9$ cfu/µg DNA. **Store Box 2 at -80°C.**

	Item	Composition	Amount
	S.O.C. Medium	2% Tryptone	6 ml
	(may be stored at +4°C	0.5% Yeast Extract	
	or room temperature)	10 mM NaCl	
		2.5 mM KCl	
		10 mM MgCl ₂	
		10 mM MgSO ₄	
		20 mM glucose	
	TOP10 cells		21 x 50 μl
	pUC19 Control DNA	10 pg/µl in 5 mM Tris-HCl, 0.5 mM EDTA, pH 8	50 µl
GeneBLAzer [™] Detection Kit	In Vitro Detection Kit or th	O® TA Expression Kits include either the ne GeneBLAzer™ <i>In Vivo</i> Detection Kit f	or fluorescence
		eporter activity. Refer to the GeneBLAz formation pertaining to each kit and a c each kit.	

Genotype of
TOP10 CellsUse this strain for general cloning. Note that this strain cannot be used for single-
strand rescue of DNA.

F- mcrA Δ (mrr-hsdRMS-mcrBC) ϕ 80lacZ Δ M15 Δ lacX74 recA1 araD139 Δ (ara-leu)7697 galU galK rpsL (Str^R) endA1 nupG

Sequencing The table below provides the sequence and amount supplied of the T7 Sequencing Primer.

Primer	Sequence	Amount
T7 Sequencing	5´-TAATACGACTCACTATAGGG-3´	328 pmoles

Accessory Products

Additional Products

The table below lists additional products that may be used with the pGeneBLAzer[™] TOPO[®] TA Expression Kits. For more information, refer to our Web site (www.invitrogen.com) or call Technical Service (see page 30).

Note: Other reagent sizes may be available.

Item	Amount	Catalog no.
Platinum [®] Taq DNA Polymerase	100 reactions	10966-018
	250 reactions	10966-026
	500 reactions	10966-034
	5000 reactions	10966-083
Taq DNA Polymerase, Recombinant	100 units	10342-053
	500 units	10342-020
Platinum [®] <i>Taq</i> DNA Polymerase High Fidelity	100 units	11304-011
One Shot [®] Kit	10 reactions	C4040-10
(TOP10 Chemically Competent E. coli)	20 reactions	C4040-03
	40 reactions	C4040-06
One Shot [®] Kit	10 reactions	C4040-50
(TOP10 Electrocompetent E. coli)	20 reactions	C4040-52
T7 Promoter Primer	2 μg (328 pmoles)	N560-02
PureLink™ HQ Mini Plasmid Purification Kit	100 reactions	K2100-01
Geneticin®	1 g	11811-023
	5 g	11811-031
	20 ml (50 mg/ml)	10131-035
	100 ml (50 mg/ml)	10131-027

Introduction

Overview	
Introduction	The pGeneBLAzer [™] TOPO [®] TA Expression Kits provide a highly efficient, 5 minute, one-step cloning strategy ("TOPO [®] Cloning") for the direct insertion of promoter sequences amplified by <i>Taq</i> polymerase into a reporter vector. You will insert your promoter sequences upstream of the β-lactamase reporter gene. Recombinant vectors can then be transfected into mammalian cells and assayed for promoter function and strength <i>in vivo</i> or <i>in vitro</i> using the GeneBLAzer [™] <i>In</i> <i>Vivo</i> or <i>In Vitro</i> Detection Kit, respectively. No ligase, post-PCR procedures, or PCR primers containing specific sequences are required. For more information about TOPO [®] Cloning and the GeneBLAzer [™] Technology, see pages 2-3.
Features of the pGeneBLAzer- TOPO [®] Vector	 The pGeneBLAzer-TOPO[®] vector contains the following elements: TOPO[®] Cloning site for rapid and efficient cloning of <i>Taq</i> polymerase-amplified PCR products <i>bla</i>(M) reporter gene to facilitate <i>in vitro</i> or <i>in vivo</i> analysis of promoter function using fluorescence detection Herpes Simplex Virus thymidine kinase (TK) polyadenylation sequence for efficient transcription termination and polyadenylation of mRNA (Cole and
	 Stacy, 1985) Neomycin resistance gene for selection of stable cell lines (Southern and Berg, 1982) pUC origin for high-copy replication and maintenance of the plasmid in <i>E. coli</i> Ampicillin resistance gene for selection in <i>E. coli</i> The control plasmid, pGeneBLAzer[™]/UbC, is included for use as a positive control for transfection and expression in mammalian cells.
Advantages of the GeneBLAzer [™] Detection System	 Using the GeneBLAzer[™] Technology and the GeneBLAzer[™] Detection System as a reporter of gene expression in mammalian cells provides the following advantages: Suitable for use as a sensitive reporter of gene expression in living mammalian cells using fluorescence microscopy. Provides a ratiometric readout to minimize differences due to variability in cell number, substrate concentration, fluorescence intensity, and emission sensitivity. Compatible with a wide variety of <i>in vivo</i> and <i>in vitro</i> applications including microplate-based transcriptional assays and flow cytometry. Provides a flexible and simple assay development platform for gene expression in mammalian cells. Using a non-toxic substrate allows continued cell culturing after quantitative analysis.

How TOPO[®] Cloning Works

How Topoisomerase I Works	Topoisomerase I from <i>Vaccinia</i> virus binds to duplex DNA at specific sites and cleaves the phosphodiester backbone after 5'-CCCTT in one strand (Shuman, 1991). The energy from the broken phosphodiester backbone is conserved by formation of a covalent bond between the 3' phosphate of the cleaved strand and a tyrosyl residue (Tyr-274) of topoisomerase I. The phospho-tyrosyl bond between the DNA and enzyme can subsequently be attacked by the 5' hydroxyl of the original cleaved strand, reversing the reaction and releasing topoisomerase (Shuman, 1994). TOPO [®] Cloning exploits this reaction to efficiently clone PCR products.
TOPO [®] Cloning	The pGeneBLAzer-TOPO [®] vector is supplied linearized with:
-	• Single 3´ thymidine (T) overhangs for TA Cloning [®]
	• Topoisomerase I covalently bound to the vector (this is referred to as "activated vector")
	<i>Taq</i> polymerase has a nontemplate-dependent terminal transferase activity that adds a single deoxyadenosine (A) to the 3' ends of PCR products. The linearized vector supplied in this kit has single, overhanging 3' deoxythymidine (T) residues. This allows PCR products to ligate efficiently into the vector.
	TOPO [®] Cloning exploits the ligation activity of topoisomerase I by providing an "activated", linearized TA vector using proprietary technology (Shuman, 1994). Ligation of the vector with a PCR product containing 3' A-overhangs is very efficient and occurs spontaneously within 5 minutes at room temperature. The TOPO [®] Cloning reaction can be transformed into chemically competent cells (provided) or electroporated directly into electrocompetent cells.
	Topoisomerase
	CCCTT GGGA PCR Product HO TTCCCC HO TTCCCC

Topoisomerase

The GeneBLAzer[™] Technology

Components of the GeneBLAzer [™] System	 The GeneBLAzer[™] System facilitates fluorescent detection of β-lactamase reporter activity in mammalian cells, and consists of two major components: The β-lactamase reporter gene, bla(M), a truncated form of the <i>E. coli bla</i> gene. When fused to promoter sequences in the pGeneBLAzer-TOPO[®] vector, the bla(M) gene functions as a reporter of promoter activity in mammalian cells. For more information about the bla(M) gene, see below. A fluorescence resonance energy transfer (FRET)-enabled substrate, CCF2 to facilitate fluorescence detection of β-lactamase reporter activity. In the absence or presence of β-lactamase reporter activity, cells loaded with the CCF2 substrate fluorescence in a population of live cells or in a cell extract of your sample to a negative control provides a means to quantitate gene expression. For more information about the CCF2 substrate and how FRET works, refer to the GeneBLAzer[™] Detection Kits manual. This manual is supplied with the pGeneBLAzer[™] TOPO[®] TA Expression Kits, but is also available for downloading from our Web site (www.invitrogen.com) or by calling Technical Service (see page 30).
β-Lactamase (<i>bla</i>) Gene	β -lactamase is the product encoded by the ampicillin resistance gene (<i>bla</i>) and is the bacterial enzyme that hydrolyzes penicillins and cephalosporins. The <i>bla</i> gene is present in many cloning vectors and allows ampicillin selection in <i>E. coli</i> . β -lactamase is not found in mammalian cells.
<i>bla</i> (M) Gene	The GeneBLAzer [™] Technology uses a modified <i>bla</i> gene as a reporter in mammalian cells. This <i>bla</i> gene is derived from the <i>E. coli TEM-1</i> gene present in many cloning vectors (Zlokarnik <i>et al.</i> , 1998), and has been modified in the following ways:
	• 72 nucleotides encoding the first 24 amino acids of β-lactamase were deleted from the N-terminal region of the gene. These 24 amino acids comprise the bacterial periplasmic signal sequence, and deleting this region allows cytoplasmic expression of β-lactamase in mammalian cells.
	• The amino acid at position 24 was mutated from His to Asp to create an optimal Kozak sequence for improved translation initiation.
	This modified reporter gene is named <i>bla</i> (M).
	Note: The <i>TEM-1</i> gene also contains 2 mutations (at nucleotide positions 452 and 753) that distinguish it from the <i>bla</i> gene in pBR322 (Sutcliffe, 1978).

Experimental Outline

Flow Chart

The flow chart below outlines the experimental steps necessary to clone and test your promoter sequences. For more details, refer to the pages indicated.

Step	Action	Page
1	Design PCR primers to clone your promoter sequence of interest into pGeneBLAzer-TOPO [®] .	5
2	Produce your PCR product.	7
3	TOPO [®] Clone your PCR product into pGeneBLAzer- TOPO [®] and transform the reaction into One Shot [®] TOP10 <i>E. coli</i> . Select for transformants on LB agar plates containing 100 μ g/ml ampicillin.	8-11
4	Analyze transformants for the presence and orientation of the insert by restriction digestion, PCR, or sequencing.	13
5	Prepare purified plasmid DNA for transfection.	16
6	Transfect your pGeneBLAzer-TOPO [®] construct into the mammalian cell line using your method of choice. Select for stable transfectants using Geneticin [®] (if desired).	16-18
7	Assay for β-lactamase reporter activity using the appropriate GeneBLAzer [™] Detection Kit.	19

Methods

General Cloning Considerations

	The second mean of the second state of the second to second state.
Introduction	In general, promoter reporter vectors can be used to analyze:
	Tissue and cell-specific promoter function
	Transcriptional enhancers in a known promoter
	Deletions within a promoter
Note	When analyzing promoters in a reporter vector, it is important to realize that sequences within the native gene can influence regulation of its own promoter. In addition, sequences within the reporter gene can also affect transcription from the promoter under study. We recommend that you verify any observations of transcriptional control of the fusion gene with expression of the native gene. S1 mapping can be used to confirm that the subcloned promoter initiates transcription at the correct site. For more information about S1 mapping, see <i>Current Protocols in Molecular Biology</i> , pages 4.6.1 to 4.6.13 (Ausubel <i>et al.</i> , 1994).
Q Important	Since initiation of translation in eukaryotes occurs at the first available AUG codon, it is important that there are no AUG codons between the start of transcription and the AUG of the reporter gene.
PCR Primer Design	Use the diagram on the next page and the sequence of your promoter to design PCR primers. Unique restriction sites may be included in the 5 [′] and 3 [′] primers to excise the fragment or facilitate analysis once it is TOPO [®] Cloned.
Note	Do not add 5 [°] phosphates to your PCR primers. Phosphates will inhibit topoisomerase I and the synthesized PCR product will not ligate into the pGeneBLAzer-TOPO [®] vector. Note that cloning efficiencies may vary depending on the 5 [°] nucleotide in the primers (see page 22).

General Cloning Considerations, continued

TOPO [®] Cloning Site of pGeneBLAzer- TOPO [®]	Use the diagram below to help you design appropriate PCR primers to clone your promoter sequence of interest into pGeneBLAzer-TOPO [®] . The pGeneBLAzer-TOPO [®] vector is supplied linearized between base pair 116 and 117. This is the TOPO [®] Cloning site. The complete sequence of pGeneBLAzer- TOPO[®] is available for downloading from our Web site (www.invitrogen.com) or by contacting Technical Service (see page 30). For a map and a description of the features of pGeneBLAzer-TOPO [®] refer to the Appendix , page 26
	the features of pGeneBLAzer-TOPO [®] , refer to the Appendix , page 26.

11	T7 promoter/priming site
71	GGTACCGAGC TCGGATCCAC TAGTCCAGTG TGGTGGAATT GCCCTT PCR Product AGGGGC CGGGAA TTCCCG
123	AAT TCG CCC TTC ACC ATG GAC CCA GAA ACG CTG GTG AAA GTA AAA GAT GCT TTA AGC GGG AAG TGG TAC CTG GGT CTT TGC GAC CAC TTT CAT TTT CTA CGA Met Asp Pro Glu Thr Leu Val Lys Val Lys Asp Ala
174	921 GAA GAT CTT CTA Glu Asp Jun Lys His Trp ***

Producing PCR Products

Introduction	Once you have decided on a PCR strategy and have synthesized the primers you are ready to produce your PCR product.					
Materials Supplied by the User	You will need the following reagents and equipment. Note: dNTPs (adjusted to pH 8) are provided in the kit.					
	• <i>Taq</i> polymerase or other suitable DNA polymerase Note: For improved specificity and higher yields, we recommend using P <i>Taq</i> DNA Polymerase available from Invitrogen (see page x for ordering is to generate your PCR product.					
	•	Thermocycler				
	•	DNA template and p	rimers for PCR product			
Polymerase Mixtures	po rat	lymerase to produce ye tio of <i>Taq</i> polymerase:p	se mixture containing <i>Taq</i> polymerase and a proofreading our PCR product; however, the mixture must contain a roofreading polymerase in excess of 10:1 to ensure the gs on the PCR product.			
	If you use polymerase mixtures that do not have enough <i>Taq</i> polymerase or a proofreading polymerase only, you may add 3' A-overhangs to your PCR product using the method on page 25.					
Producing PCR Products	1.	plasmid DNA as a ter as a template. Use the template. Be sure to in	50 μl PCR reaction. Use less DNA if you are using mplate and more DNA if you are using genomic DNA e cycling parameters suitable for your primers and nclude a 7 to 30 minute extension at 72°C after the last ll PCR products are full length and 3' adenylated.			
		DNA Template	10-100 ng			
		10X PCR Buffer	5 µl			
		50 mM dNTPs	0.5 µl			
		Primers	100-200 ng each			
		Sterile water	add to a final volume of 49 µl			
		<u>Taq Polymerase (1 un</u>	<u>it/μl) 1 μl</u>			
		Total Volume	50 µl			
	2.		ict by agarose gel electrophoresis. You should see a If you do not see a single band, refer to the Note below.			
Note	yo cai Al sm	ur fragment before pro re to avoid sources of n ternatively, you may o nearing (Innis <i>et al.</i> , 199	gle, discrete band from your PCR, you may gel-purify ceeding to TOPO [®] Cloning (see page 23). Take special cuclease contamination and long exposure to UV light. ptimize your PCR to eliminate multiple bands and 0). The PCR Optimizer [™] Kit (Catalog no. K1220-01) you optimize your PCR.			

Setting Up the TOPO[®] Cloning Reaction

Introduction

TOPO[®] Cloning technology allows you to produce your PCR products, ligate them into pGeneBLAzer-TOPO[®], and transform the recombinant vector into One Shot[®] TOP10 *E. coli*, all in one day. It is important to have everything you need set up and ready to use to ensure you obtain the best possible results. We suggest that you read this section and the section entitled **Transforming One Shot[®] TOP10 Competent Cells** before beginning. If this is the first time you have TOPO[®] Cloned, perform the control reactions on pages 20-22 in parallel with your samples.



We have found that including salt (200 mM NaCl, 10 mM MgCl₂) in the TOPO[®] Cloning reaction can increase the number of transformants 2- to 3-fold. In addition, incubating the reaction mixture for greater than 5 minutes in the presence of salt can also increase the number of transformants. This is in contrast to earlier experiments **without salt** where the number of transformants decreases as the incubation time increases beyond 5 minutes.

Including salt in the TOPO[®] Cloning reaction allows for longer incubation times because it prevents topoisomerase I from rebinding and potentially nicking the DNA after ligating the PCR product and dissociating from the DNA. The result is more intact molecules, leading to higher transformation efficiencies.

Using Salt Solution in the TOPO [®] Cloning Reaction	You will perform TOPO [®] Cloning in a reaction buffer containing salt (<i>i.e.</i> using the stock salt solution provided in the kit). Note that the amount of salt added to the TOPO [®] Cloning reaction varies depending on whether you plan to transform chemically competent cells (provided) or electrocompetent cells (see page x for ordering information).		
	• If you are transforming chemically competent <i>E. coli</i> , use the stock Salt Solution as supplied and set up the TOPO [®] Cloning reaction as directed on the next page.		
	• If you are transforming electrocompetent <i>E. coli</i> , the amount of salt in the TOPO [®] Cloning reaction must be reduced to 50 mM NaCl, 2.5 mM MgCl ₂ to prevent arcing during electroporation. Dilute the stock Salt Solution 4-fold with water to prepare a 300 mM NaCl, 15 mM MgCl ₂ Dilute Salt Solution. Use the Dilute Salt Solution to set up the TOPO [®] Cloning reaction as directed on the next page.		
Materials Needed	You should have the following materials on hand before beginning:		
	Your PCR product (freshly prepared)		
	• pGeneBLAzer-TOPO [®] vector (supplied with the kit; keep at -20°C until use)		
	• Salt Solution (supplied with the kit) or Dilute Salt Solution as appropriate		
	• Sterile water (supplied with the kit)		

Setting Up the TOPO[®] Cloning Reaction, continued

Performing the TOPO[®] Cloning Reaction

Use the procedure below to perform the TOPO[®] Cloning reaction. Set up the TOPO[®] Cloning reaction using the reagents in the order shown, and depending on whether you plan to transform chemically competent *E. coli* or electrocompetent *E. coli*.

Note: The red or yellow color of the TOPO[®] vector solution is normal and is used to visualize the solution.

Reagents*	Chemically Competent E. coli	Electrocompetent E. coli
Fresh PCR product	0.5 to 4 μl	0.5 to 4 μl
Salt Solution	1 µl	
Dilute Salt Solution (1:4)		1 µl
Sterile Water	add to a final volume of 5 µl	add to a final volume of 5 μ l
TOPO [®] vector	1 μl	1 µl
Final Volume	6 µl	6 µl

*Store all reagents at -20°C when finished. Salt solutions and water can be stored at room temperature or +4°C.

1. Mix reaction gently and incubate for 5 minutes at room temperature.

Note: For most applications, 5 minutes will yield plenty of colonies for analysis. Depending on your needs, the length of the TOPO[®] Cloning reaction can be varied from 30 seconds to 30 minutes. For routine subcloning of PCR products, 30 seconds may be sufficient. For large PCR products (> 1 kb) or if you are TOPO[®] Cloning a pool of PCR products, increasing the reaction time will yield more colonies.

2. Place the reaction on ice and proceed to **Transforming One Shot**[®] **TOP10 Competent Cells** (next page).

Note: You may store the TOPO® Cloning reaction at -20°C overnight.

Transforming One Shot[®] TOP10 Competent Cells

Introduction	Once you have performed the TOPO [®] Cloning reaction, you will transform your pGeneBLAzer-TOPO [®] construct into competent <i>E. coli</i> . One Shot [®] TOP10 Chemically Competent <i>E. coli</i> (Box 2) are included with the kit to facilitate transformation, however, you may also transform electrocompetent cells (see page x for ordering information). Protocols to transform chemically competent or electrocompetent <i>E. coli</i> are provided in this section.
Materials Supplied by the User	In addition to general microbiological supplies (<i>i.e.</i> plates, spreaders), you will need the following reagents and equipment.
	• 42°C water bath (or electroporator with cuvettes, optional)
	• LB plates containing 100 µg/ml ampicillin (two for each transformation)
	• 37°C shaking and non-shaking incubator
Note	There is no blue-white screening for the presence of inserts. Individual recombinant plasmids need to be analyzed by restriction analysis or sequencing for the presence and orientation of insert. The T7 Sequencing Primer is included in the kit to facilitate sequencing across the junction of the TOPO [®] Cloning site and your PCR product to confirm orientation.
Preparing for Transformation	For each transformation, you will need one vial of competent cells and two selective plates.
	• Equilibrate a water bath to 42°C (for chemical transformation) or set up your electroporator if you are using electrocompetent <i>E. coli</i> .
	• Warm the vial of S.O.C. Medium from Box 2 to room temperature.
	• Warm selective plates at 37°C for 30 minutes.
	• Thaw <u>on ice</u> 1 vial of One Shot [®] TOP10 cells from Box 2 for each transformation.

Transforming One Shot[®] TOP10 Competent Cells, continued

One Shot [®] TOP10 Chemical Transformation	1.	Add 2 µl of the TOPO [®] Cloning reaction from Step 2, page 9 into a vial of One Shot [®] TOP10 Chemically Competent <i>E. coli</i> and mix gently. Do not mix by pipetting up and down.
	2.	Incubate on ice for 5 to 30 minutes.
		Note : Longer incubations on ice seem to have a minimal effect on transformation efficiency. The length of the incubation is at the user's discretion.
	3.	Heat-shock the cells for 30 seconds at 42°C without shaking.
	4.	Immediately transfer the tubes to ice.
	5.	Add 250 µl of room temperature S.O.C. Medium.
	6.	Cap the tube tightly and shake the tube horizontally (200 rpm) at 37°C for 1 hour.
	7.	Spread 25-200 µl from each transformation on a pre-warmed selective plate and incubate overnight at 37°C. We recommend plating two different volumes to ensure that at least one plate will have well-spaced colonies.
	8.	An efficient TOPO [®] Cloning reaction will produce hundreds of colonies. Pick ~10 colonies for analysis (see Analyzing Transformants , next page).
Transformation by Electroporation		e only electrocompetent cells for electroporation to avoid arcing. Do not use e One Shot® TOP10 chemically competent cells for electroporation.
	1.	Add 2 µl of the TOPO [®] Cloning reaction from Step 2, page 9 into 50 µl of electrocompetent E. coli and mix gently. Do not mix by pipetting up and down. Avoid formation of bubbles. Transfer the electrocompetent cells into a 0.1 cm cuvette.
	2.	Electroporate your samples using your own protocol and your electroporator.
		Note: If you have problems with arcing, see the next page.
	3.	Immediately add 250 μl of room temperature S.O.C. Medium.
	4.	Transfer the solution to a 15 ml snap-cap tube (<i>i.e.</i> Falcon) and shake for at least 1 hour at 37°C to allow expression of the antibiotic resistance marker.
	5.	Spread 10-50 μ l from each transformation on a pre-warmed selective plate and incubate overnight at 37°C. To ensure even spreading of small volumes, add 20 μ l of S.O.C. Medium. We recommend plating two different volumes to ensure that at least one plate will have well-spaced colonies.
	6.	An efficient TOPO [®] Cloning reaction will produce hundreds of colonies. Pick ~10 colonies for analysis (see Analyzing Transformants , page 13).
		continued on next page

Transforming One Shot[®] TOP10 Competent Cells, continued



To prevent arcing of your samples during electroporation, the volume of cells should be between 50 and 80 μl (0.1 cm cuvettes) or 100 to 200 μl (0.2 cm cuvettes).

If you experience arcing during transformation, try one of the following options:

- Reduce the voltage normally used to charge your electroporator by 10%.
- Reduce the pulse length by reducing the load resistance to 100 ohms.
- Ethanol precipitate the TOPO[®] Cloning reaction and resuspend in water prior to electroporation.

Analyzing Transformants

Analyzing Positive Clones	1.	Pick 10 colonies and culture them overnight in 3-5 ml LB medium containing 100 μ g/ml ampicillin.			
	2.	Isolate plasmid DNA using your method of choice. We recommend using the PureLink [™] HQ Mini Plasmid Purification Kit (Catalog no. K2100-01) available from Invitrogen.			
	3.	Analyze the plasmids for the presence of the insert and orientation by restriction analysis or by sequencing. Use the T7 Sequencing Primer included in the kit to help you verify the orientation of your insert by sequencing. Refer to the diagram on page 6 for sequence surrounding the TOPO Cloning [®] site. For the complete sequence of pGeneBLAzer-TOPO [®] , see our Web site (www.invitrogen.com) or contact Technical Service (page 30).			
Analyzing Transformants by PCR	Sec de tin ob	bu may analyze positive transformants using PCR. For PCR primers, use the T7 quencing Primer and a primer that binds within your insert. You will have to termine the amplification conditions. If you are using this technique for the first ne, we recommend performing restriction analysis in parallel. Artifacts may be tained because of mispriming or contaminating template. The protocol below is ovided for your convenience. Other protocols may be suitable.			
	Materials Needed				
	PCR SuperMix High Fidelity (Invitrogen, Catalog no. 10790-020)				
	Appropriate forward and reverse PCR primers (20 μ M each)				
	Procedure				
	1.	For each sample, aliquot 48 μ l of PCR SuperMix High Fidelity into a 0.5 ml microcentrifuge tube. Add 1 μ l each of the forward and reverse PCR primer.			
	2.	Pick 10 colonies and resuspend them individually in 50 μ l of the PCR cocktail from Step 1, above. Don't forget to make a patch plate to preserve the colonies for further analysis.			
	3.	Incubate the reaction for 10 minutes at 94°C to lyse the cells and inactivate nucleases.			
	4.	Amplify for 20 to 30 cycles.			
	5.	For the final extension, incubate at 72°C for 10 minutes. Store at +4°C.			
	6.	Visualize by agarose gel electrophoresis.			
Q Important	coi	you have problems obtaining transformants or the correct insert, perform the ntrol reactions described on page 20-22. These reactions will help you publeshoot your experiment.			

Analyzing Transformants, continued

Long-Term Storage	Once you have identified the correct clone, be sure purify the colony and mak glycerol stock for long-term storage. We recommend that you store a stock of plasmid DNA at -20°C.	
	1.	Streak the original colony on LB plates containing 100 μ g/ml ampicillin.
	2.	Isolate a single colony and inoculate into 1-2 ml of LB containing 100 μ g/ml ampicillin.
	3.	Grow until culture reaches stationary phase.

- 4. Mix 0.85 ml of culture with 0.15 ml of sterile glycerol and transfer to a cryovial.
- 5. Store at -80°C.

Optimizing the TOPO[®] Cloning Reaction

Introduction	Use the information below to help you optimize the TOPO [®] Cloning reaction for your particular needs.
Faster Subcloning	The high efficiency of TOPO [®] Cloning allows you to streamline the cloning process. If you routinely clone PCR products and wish to speed up the process, consider the following:
	 Incubate the TOPO[®] Cloning reaction for only 30 seconds instead of 5 minutes.
	You may not obtain the highest number of colonies, but with the high efficiency of TOPO [®] Cloning, most of the transformants will contain your insert.
	 After adding 2 μl of the TOPO[®] Cloning reaction to chemically competent cells, incubate on ice for only 5 minutes.
	Increasing the incubation time to 30 minutes does not significantly improve transformation efficiency.
More Transformants	If you are TOPO [®] Cloning large PCR products, toxic genes, or cloning a pool of PCR products, you may need more transformants to obtain the clones you want. To increase the number of colonies:
	 Incubate the salt-supplemented TOPO[®] Cloning reaction for 20 to 30 minutes instead of 5 minutes.
	Increasing the incubation time of the salt-supplemented TOPO [®] Cloning reaction allows more molecules to ligate, increasing the transformation efficiency. Addition of salt appears to prevent topoisomerase from rebinding and nicking the DNA after it has ligated the PCR product and dissociated from the DNA.
Cloning Dilute	To clone dilute PCR products, you may:
PCR Products	• Increase the amount of the PCR product
	• Incubate the TOPO [®] Cloning reaction for 20 to 30 minutes
	Concentrate the PCR product by precipitation

Transfecting Cells

Introduction	Once you have obtained the desired pGeneBLAzer-TOPO [®] construct, you are ready to transfect the plasmid into the mammalian cell line of choice. Guidelines for transfection are provided below. If you wish to generate stable cell lines, see additional guidelines provided in the next section.		
	If you plan to detect β -lactamase reporter activity <i>in vivo</i> using the GeneBLAzer TM In Vivo Detection Kit (supplied with Catalog no. 12578-027 only), note that a number of factors including cell type and cell density can influence the degree of the fluorescence signal detected. We recommend taking these factors into account when designing your transfection experiment. For more information, refer to the section entitled General Guidelines to Use the GeneBLAzerTM In Vivo Detection Kit in the GeneBLAzer TM Detection Kit manual.		
Plasmid Preparation	Plasmid DNA for transfection into eukaryotic cells must be very clean and free from phenol and sodium chloride. Contaminants will kill the cells and salt will interfere with lipid complexing decreasing transfection efficiency. We recommend isolating plasmid DNA using the PureLink [™] HQ Mini Plasmid Purification Kit (Catalog no. K2100-01) or CsCl gradient centrifugation.		
Controls	We recommend including a positive and a negative control to evaluate expression and detection β-lactamase. A negative control can be either a mock transfection or a pGeneBLAzer-TOPO [®] construct containing non-promoter DNA sequences (<i>i.e.</i> stuffer DNA). For a positive control, use the pGeneBLAzer [™] /UbC plasmid included in the kit (see below for more information).		
Positive Control	pGeneBLAzer TM /UbC is provided as a positive control for mammalian cell transfection, expression, and detection (see page 28 for a map) and may be used to optimize detection conditions in your cell line. In this vector, the human ubiquitin C (UbC) promoter (Nenoi <i>et al.</i> , 1996) controls expression of the β -lactamase reporter gene.		
	To propagate and maintain the plasmid:		
	 Use the stock solution to transform a <i>rec</i>A, <i>end</i>A <i>E. coli</i> strain such as TOP10, DH5α[™], or equivalent. 		
	2. Select transformants on LB agar plates containing 100 μ g/ml ampicillin.		
	 Prepare a glycerol stock of a transformant containing plasmid for long-term storage. 		

Transfecting Cells, continued

Methods of Transfection For established cell lines (*e.g.* HeLa), consult original references or the supplier of your cell line for the optimal method of transfection. We recommend that you follow exactly the protocol for your cell line. Pay particular attention to medium requirements, when to pass the cells, and at what dilution to split the cells. Further information is provided in *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994). Methods for transfection include calcium phosphate (Chen and Okayama, 1987; Wigler *et al.*, 1977), lipid-mediated (Felgner *et al.*, 1989; Felgner and Ringold, 1989) and electroporation (Chu *et al.*, 1987; Shigekawa and Dower, 1988). For high efficiency transfection in a broad range of mammalian cell lines, we recommend using Lipofectamine[™] 2000 Reagent (Catalog no. 11668-027)

available from Invitrogen. For more information about Lipofectamine[™] 2000 and the other transfection reagents available from Invitrogen, visit our Web site (www.invitrogen.com) or contact Technical Service (see page 30).

Creating Stable Cell Lines

Introduction	The pGeneBLAzer-TOPO [®] vector contains the neomycin resistance gene to allow selection of stable cell lines using Geneticin [®] . If you wish to create stable cell lines, transfect your construct into the mammalian cell line of choice and select for foci using Geneticin [®] . General information and guidelines are provided below.
Geneticin [®]	Geneticin [®] blocks protein synthesis in mammalian cells by interfering with ribosomal function. It is an aminoglycoside, similar in structure to neomycin, gentamycin, and kanamycin. Expression in mammalian cells of the bacterial aminoglycoside phosphotransferase gene (APH), derived from Tn5, results in detoxification of Geneticin [®] (Southern and Berg, 1982).
Geneticin [®] Selection Guidelines	 Geneticin[®] is available from Invitrogen (see page x for ordering information). Use as follows: 1. The liquid form of Geneticin[®] is supplied as a 50 mg/ml stock solution and is ready-to-use. To use the powder form of Geneticin[®], prepare a 50 mg/ml stock solution in buffered solution (<i>e.g.</i> 100 mM HEPES, pH 7.3).
	 Use 100 to 1000 μg/ml of Geneticin[®] in complete growth medium. Test varying concentrations of Geneticin[®] on your cell line to determine the concentration that kills your cells (kill curve). Cells differ in their susceptibility to Geneticin[®]. Note: Cells will divide once or twice in the presence of lethal doses of Geneticin[®], so the effects of the drug take several days to become apparent. Complete selection can take from 2 to 4 weeks of growth in selective medium.
Generating Stable Cell Lines	Once you have determined the appropriate Geneticin [®] concentration to use for selection, you can generate a stable cell line expressing your pGeneBLAzer-TOPO [®] construct.
	1. Transfect the mammalian cell line of interest with the pGeneBLAzer-TOPO [®] construct using your transfection method of choice.
	2. 24 hours after transfection, wash the cells and add fresh growth medium.
	3. 48 hours after transfection, split the cells into fresh growth medium such that they are no more than 25% confluent. If the cells are too dense, the antibiotic will not kill the cells. Antibiotics work best on actively dividing cells.
	4. Incubate the cells at 37°C for 2-3 hours until they have attached to the culture dish.
	 Remove the growth medium and replace with fresh growth medium containing the Geneticin[®] at the pre-determined concentration required for your cell line.
	6. Feed the cells with selective media every 3-4 days until Geneticin [®] -resistant colonies can be identified.
	 Pick at least 5 Geneticin[®]-resistant colonies and expand them to assay for recombinant protein expression.

Detecting β -Lactamase Reporter Activity

Depending on the kit you are using, you will assay for β-lactamase reporter activity using <i>in vivo</i> or <i>in vitro</i> detection methods. A brief description of each GeneBLAzer [™] Detection Kit is provided below. For detailed information about each kit, refer to the GeneBLAzer [™] Detection Kits manual.
Using the GeneBLAzer TM In Vitro Detection Kit allows you to quantitate the amount of intracellular β -lactamase in cells based on the β -lactamase enzyme activity in lysates.
To detect β -lactamase reporter activity in mammalian cell lysates, you will use the CCF2-FA substrate. CCF2-FA is the non-esterified, free acid form of CCF2, and is recommended for <i>in vitro</i> use because it is readily soluble in aqueous solution and may be added directly to pre-made cell lysates. Once added to cell lysates, you may quantitate the fluorescence signal using a fluorescence plate reader or a fluorometer.
To prepare cell lysates from mammalian cells containing the <i>bla</i> (M) reporter gene, you must use a method that will preserve the activity of the β-lactamase enzyme. Refer to the GeneBLAzer [™] Detection Kits manual for detailed guidelines and protocols to prepare the CCF2-FA stock solution, prepare cell lysates and samples, and detect CCF2-FA fluorescence signal.
Using the GeneBLAzer TM In Vivo Detection Kit allows you to measure β -lactamase reporter activity in live mammalian cells. Once β -lactamase reporter activity has been measured, cells may be cultured further for use in additional assays or other downstream applications.
To detect β-lactamase reporter activity in live mammalian cells, you will use the CCF2-AM substrate. CCF2-AM is the membrane-permeable, esterified form of CCF2, and is recommended for <i>in vivo</i> use because it is non-toxic, lipophilic and readily enters the cell. Once cells are "loaded" with CCF2-AM, you may quantitate fluorescence signal using a variety of methods. Refer to the GeneBLAzer [™] Detection Kits manual for detailed guidelines and protocols to prepare the CCF2-AM stock solution, load cells with CCF2-AM substrate, and detect CCF2 fluorescence signal.

Appendix

Performing the Control Reactions

Introduction	firs cor pro usi Clo	e recommend performing the st time you use the kit to help atrol reactions involves prod pmoter and the LacZα proteing ng this product directly in a pming of the control PCR pro ataining ampicillin and X-ga	p you evaluate yo ucing a control P n) using the reag TOPO [®] Cloning : duct will yield bl	our results. Perform CR product (contain ents included in the reaction. Successful	ing the ning the <i>lac</i> e kit and I TOPO [®]
Before Starting	Pre	Prepare the following reagents before performing the control reaction:			
_	•	• 40 mg/ml X-gal in dimethylformamide (Catalog no. 15520-034)			
	•	LB plates containing 100 με transformation)	g/ml ampicillin a	nd X-gal (two per	
		To add X-gal to previously 40 µl of the 40 mg/ml stock dry 15 minutes. Protect pla	solution onto th	-	-
Producing the Control PCR	1.	To produce the 500 bp cont LacZ α , set up the following	-	containing the <i>lac</i> p	promoter and
Product		Control DNA Template (50	ng)	1 µl	
		10X PCR Buffer		5 µl	
		50 mM dNTPs		0.5 µl	
		Control PCR Primers (0.1 µ	ıg∕µl each)	2 µl	
		Sterile Water	-	40.5 µl	
		<u>Taq Polymerase (1 unit/µl)</u>		<u>1 µl</u>	
		Total Volume		50 µl	
	2.	Overlay with 70 µl (1 drop)) of mineral oil, if	required.	
	3.	Amplify using the followin	ng cycling parame	eters:	
		Step	Time	Temperature	Cycles
		Initial Denaturation	2 minutes	94°C	1X
		Denaturation	1 minute	94°C	
		Annealing	1 minute	60°C	25X
		Extension	1 minute	72°C	
		Final Extension	7 minutes	72°C	1X

4. Remove 10 μl from the reaction and analyze by agarose gel electrophoresis. A discrete 500 bp band should be visible. Proceed to **Control TOPO**[®] **Cloning Reactions**, next page.

Performing the Control Reactions, continued

Control TOPO[®] Cloning Reactions

Use the control PCR product produced on the previous page and pGeneBLAzer-TOPO[®] to set up two 6 μ l TOPO[®] Cloning reactions as described below.

1. Set up control TOPO[®] Cloning reactions:

Reagent	"Vector Only"	"Vector + PCR Insert"
Sterile Water	4 µl	3 µl
Salt Solution or Dilute Salt Solution	1 µl	1 μl
Control PCR Product		1 μl
TOPO [®] vector	1 µl	1 μl

- 2. Incubate at room temperature for **5 minutes** and place on ice.
- 3. Transform 2 μ l of each reaction into separate vials of One Shot[®] TOP10 cells (page 11).
- 4. Spread 10-50 μ l of each transformation mix onto LB plates containing 100 μ g/ml ampicillin and X-Gal. Be sure to plate two different volumes to ensure that at least one plate has well-spaced colonies. To plate small volumes, add 20 μ l of S.O.C. Medium to allow even spreading.
- 5. Incubate overnight at 37°C.

What to ExpectHundreds of colonies from the vector + PCR insert reaction should be produced.
Greater than 85% of these will be blue and contain the 500 bp insert. Very few
colonies (<10% of the vector + PCR insert) will be present on the vector only
plate. These colonies should be white.

Transformation
ControlpUC19 plasmid is included to check the transformation efficiency of the One
Shot® TOP10 competent *E. coli.* Transform one vial of One Shot® TOP10 cells with
10 pg of pUC19 using the protocol on page 11. Plate 10 µl of the transformation
mixture plus 20 µl S.O.C. Medium on LB plates containing 100 µg/ml ampicillin.
Transformation efficiency should be ~1 x 10° cfu/µg DNA.

Performing the Control Reactions, continued

Factors Affecting Cloning Efficiency

Note that the following variables may influence the cloning efficiency. Most of these are easily corrected, but if you are cloning large inserts, you may not obtain the expected \geq 85% cloning efficiency.

Variable	Solution
pH>9	Check the pH of the PCR amplification reaction and adjust with 1 M Tris-HCl, pH 8.
Incomplete extension during PCR	Be sure to include a final extension step of 7 to 30 minutes during PCR. Longer PCR products will need a longer extension time.
Cloning large inserts (>3 kb)	Gel-purify as described on page 23.
Excess (or overly dilute) PCR product	Reduce (or concentrate) the amount of PCR product. Note that you can add up to $4 \mu l$ of the PCR reaction to the TOPO [®] Cloning reaction.
Cloning blunt-ended fragments	Add 3' A-overhangs by incubating with <i>Taq</i> polymerase (see page 25).
PCR cloning artifacts ("false positives")	TOPO [®] Cloning is very efficient for small fragments (< 100 bp) present in certain PCR reactions. Gel-purify your PCR product (see page 23).
PCR product does not contain sufficient 3´ A-overhangs even	Increase the time of the final extension to ensure that the 3 [°] ends are adenylated.
though you used <i>Taq</i> polymerase	Note that <i>Taq</i> polymerase is less efficient at adding a nontemplate 3' A next to another A. <i>Taq</i> is most efficient at adding a nontemplate 3' A next to a C. You may have to redesign your primers so that they contain a 5' G instead of a 5' T (Brownstein <i>et al.</i> , 1996).
Size of promoter sequences cloned	For large plasmids, you may have to use electroporation to transform into <i>E. coli</i> . Do not use the chemically competent TOP10 cells included in the kit for electroporation. Use electrocompetent TOP10 cells (see page x for ordering information).

Gel Purifying PCR Products

Introduction	(> pro Th Re:	hearing, multiple banding, primer-dimer artifacts, or large PCR products 1 kb) may necessitate gel purification. If you intend to purify your PCR oduct, be extremely careful to remove all sources of nuclease contamination. ere are many protocols to isolate DNA fragments or remove oligonucleotides. fer to <i>Current Protocols in Molecular Biology</i> , Unit 2.6 (Ausubel <i>et al.</i> , 1994) for e most common protocols. Three simple protocols are provided below.
Note	wi	oning efficiency may decrease with purification of the PCR product. You may sh to optimize your PCR to produce a single band (see Producing PCR pducts , page 7).
Using the S.N.A.P. [™] Gel		e S.N.A.P.™ Gel Purification Kit (Catalog no. K1999-25) allows you to rapidly rify PCR products from regular agarose gels.
Purification Kit	1.	Electrophorese amplification reaction on a 1 to 5% regular TAE agarose gel.
		Note : Do not use TBE to prepare agarose gels. Borate will interfere with the sodium iodide step, below
	2.	Cut out the gel slice containing the PCR product and melt it at 65°C in 2 volumes of 6 M sodium iodide solution.
	3.	Add 1.5 volumes of Binding Buffer.
	4.	Load solution (no more than 1 ml at a time) from Step 3 onto a S.N.A.P. [™] column. Centrifuge 1 minute at 3000 x g in a microcentrifuge and discard the supernatant.
	5.	If you have solution remaining from Step 3, repeat Step 4.
	6.	Add 900 µl of the Final Wash Buffer.
	7.	Centrifuge 1 minute at full speed in a microcentrifuge and discard the flow-through.
	8.	Repeat Step 7.
	9.	Elute the purified PCR product in 40 μ l of TE or sterile water. Use 4 μ l for the TOPO [®] Cloning reaction and proceed as described on page 9.
Quick S.N.A.P. [™] Method	pro for	even easier method is to simply cut out the gel slice containing your PCR oduct, place it on top of the S.N.A.P. ^{\mathbb{M}} column bed, and centrifuge at full speed 10 seconds. Use 1-2 μ l of the flow-through in the TOPO [®] Cloning reaction age 9). Be sure to make the gel slice as small as possible for best results.

Gel Purifying PCR Products, continued

Low-Melt Agarose Method	pu	you prefer to use low-melt agarose, use the procedure below. Note that gel rification will result in dilution of your PCR product and a potential loss of oning efficiency.
	1.	Electrophorese as much as possible of your PCR reaction on a low-melt agarose gel (0.8 to 1.2%) in TAE buffer.
	2.	Visualize the band of interest and excise the band.
	3.	Place the gel slice in a microcentrifuge tube and incubate the tube at 65°C until the gel slice melts.
	4.	Place the tube at 37°C to keep the agarose melted.
	5.	Add 4 µl of the melted agarose containing your PCR product to the TOPO [®] Cloning reaction as described on page 9.
	6.	Incubate the TOPO [®] Cloning reaction at 37°C for 5 to 10 minutes . This is to keep the agarose melted.
	7.	Transform 2 to 4 μ l directly into One Shot [®] TOP10 chemically competent <i>E. coli</i> using the procedure on page 11.


Adding 3' A-Overhangs Post-Amplification

Introduction	Direct cloning of DNA amplified by a thermostable, proofreading polymerase such as Platinum [®] <i>Pfx</i> DNA Polymerase into TOPO TA Cloning [®] vectors is often difficult because of very low cloning efficiencies. These low efficiencies are caused by the 3′ to 5′ exonuclease activity associated with proofreading polymerases which removes the 3′ A-overhangs necessary for TA Cloning [®] . A simple method is provided below to clone these blunt-ended fragments.
Before Starting	You will need the following items:
U	• <i>Taq</i> polymerase
	• A heat block equilibrated to 72°C
	Phenol-chloroform (optional)
	• 3 M sodium acetate (optional)
	• 100% ethanol (optional)
	• 80% ethanol (optional)
	• TE buffer (optional)
Procedure	This is just one method for adding 3 ⁻ adenines. Other protocols may be suitable.
	1. After amplification with a proofreading polymerase, place vials on ice and add 0.7-1 unit of <i>Taq</i> polymerase per tube. Mix well. It is not necessary to change the buffer.
	2. Incubate at 72°C for 8-10 minutes (do not cycle).
	3. Place the vials on ice. Proceed to TOPO [®] Cloning (see page 9).
	Note: If you plan to store your sample(s) overnight before proceeding with TOPO [®] Cloning, you may want to extract your sample(s) with phenol-chloroform to remove the polymerases. After phenol-chloroform extraction, precipitate the DNA with ethanol and resuspend the DNA in TE buffer to the starting volume of the amplification reaction.
Note	You may also gel-purify your PCR product after amplification with proofreading polymerase (see previous page). After purification, add <i>Taq</i> polymerase buffer, dATP, and 0.5 unit of <i>Taq</i> polymerase and incubate 10-15 minutes at 72°C. Use 4μ l in the TOPO [®] Cloning reaction.

Map and Features of pGeneBLAzer-TOPO[®]

Мар

The figure below summarizes the features of the pGeneBLAzer-TOPO[®] vector. The vector is supplied linearized between base pairs 116 and 117. This is the TOPO[®] Cloning site. The complete nucleotide sequence is available for downloading from our Web site (www.invitrogen.com) or from Technical Service (see page 30).



(c) = complementary strand

Map and Features of pGeneBLAzer-TOPO[®], continued

Features of the Vector


The pGeneBLAzer-TOPO[®] vector (5380 bp) contains the following elements. All features have been functionally tested.

Feature	Benefit
T7 promoter/priming site	Allows for <i>in vitro</i> transcription in the sense orientation and sequencing through the insert.
TOPO [®] Cloning site	Allows insertion of your PCR product containing the promoter of interest upstream of the <i>bla</i> (M) reporter gene.
<i>bla</i> (M) reporter gene	Allows assay of promoter function either <i>in vitro</i> or <i>in vivo</i> .
Herpes Simplex Virus thymidine kinase (TK) polyadenylation signal	Allows efficient transcription termination and polyadenylation of mRNA (Cole and Stacy, 1985).
f1 origin	Allows single-stranded DNA rescue.
SV40 early promoter and origin	Allow efficient, high-level expression of the neomycin resistance gene and episomal replication in cells expressing the SV40 large T antigen.
Neomycin resistance gene	Allows selection of stable transfectants in mammalian cells (Southern and Berg, 1982).
SV40 polyadenylation signal	Allows efficient transcription termination and polyadenylation of mRNA.
pUC origin	Allows high-copy number replication and maintenance in <i>E. coli</i> .
Ampicillin resistance gene	Allows selection of transformants in <i>E. coli</i> .

Map of pGeneBLAzer[™]/UbC

Description

pGeneBLAzer[™]/UbC (6620 bp) is a control vector containing the human ubiquitin C (UbC) promoter (Nenoi *et al.*, 1996; Wulff *et al.*, 1990) upstream of the *bla*(M) reporter gene. The vector was constructed by amplifying a DNA fragment containing the UbC promoter and TOPO[®] Cloning the PCR product into pGeneBLAzer-TOPO[®]. The complete nucleotide sequence for pGeneBLAzer[™]/UbC is available for downloading from our Web site (www.invitrogen.com) or from Technical Service (see page 30).



Comments for pGeneBLAzer[™]/UBC 6620 nucleotides

T7 promoter/priming site: bases 17-36 UbC promoter: bases 129-1347 β -lactamase *bla*(M) reporter gene: bases 1378-2172 TK polyadenylation signal: bases 2180-2450 f1 origin: bases 2487-2915 SV40 early promoter and origin: bases 2942-3250 Neomycin resistance gene: bases 3325-4119 SV40 early polyadenylation signal: bases 4293-4423 pUC origin (c): bases 4806-5479 Ampicillin resistance gene (c): bases 5624-6484 Ampicillin promoter (c): bases 6485-6583

(c) = complementary strand

Recipes

LB (Luria-Bertani) Medium and Plates	0.5 1.0	% Tryptone % Yeast Extract % NaCl I 7.0		
	1.	For 1 liter, dissolve 10 g tryptone, 5 g yeast extract, and 10 g NaCl in 950 ml deionized water.		
	2.	Adjust the pH of the solution to 7.0 with NaOH and bring the volume up to 1 liter.		
	3.	Autoclave on liquid cycle for 20 minutes at 15 psi. Allow solution to cool to 55° C and add 100 µg/ml ampicillin, if needed.		
	4.	Store at room temperature or at +4°C.		
	LB agar plates			
	1.	Prepare LB medium as above, but add 15 g/L agar before autoclaving.		
	2.	Autoclave on liquid cycle for 20 minutes at 15 psi.		
	3.	After autoclaving, cool to ~55°C, add 100 μ g/ml of ampicillin, and pour into 10 cm plates.		
	4.	Let harden, then invert and store at +4°C, in the dark.		

Technical Service

World Wide Web



Visit the Invitrogen Web Resource using your World Wide Web browser. At the site, you can:

- Get the scoop on our hot new products and special product offers
- View and download vector maps and sequences
- Download manuals in Adobe® Acrobat® (PDF) format
- Explore our catalog with full color graphics
- Obtain citations for Invitrogen products
- Request catalog and product literature

Once connected to the Internet, launch your web browser (Internet Explorer 5.0 or newer or Netscape 4.0 or newer), then enter the following location (or URL):

http://www.invitrogen.com

...and the program will connect directly. Click on underlined text or outlined graphics to explore. Don't forget to put a bookmark at our site for easy reference!

Contact Us For more information or technical assistance, please call, write, fax, or email. Additional international offices are listed on our web page (www.invitrogen.com).

Corporate Headquarters:	Japanese Headquarters:	European Headquarters:
Invitrogen Corporation	Invitrogen Japan K.K.	Invitrogen Ltd
1600 Faraday Avenue	Nihonbashi Hama-Cho Park	Inchinnan Business Park
Carlsbad, CA 92008	Bldg. 4F	3 Fountain Drive
USA	2-35-4, Hama-Cho, Nihonbashi	Paisley PA4 9RF, UK
Tel: 1 760 603 7200	Tel: 81 3 3663 7972	Tel: +44 (0) 141 814 6100
Tel (Toll Free): 1 800 955 6288	Fax: 81 3 3663 8242	Tech Fax: +44 (0) 141 814 6117
Fax: 1 760 602 6500	E-mail: jpinfo@invitrogen.com	E-mail: eurotech@invitrogen.com
E-mail: tech_service@invitrogen.com		

MSDS Requests

To request an MSDS, visit our Web site at www.invitrogen.com. On the home page, go to 'Technical Resources', select 'MSDS', and follow instructions on the page.

Technical Service, continued

Limited Warranty

Invitrogen is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should have any questions or concerns about an Invitrogen product or service, contact our Technical Service Representatives.

Invitrogen warrants that all of its products will perform according to specifications stated on the certificate of analysis. The company will replace, free of charge, any product that does not meet those specifications. <u>This warranty</u> <u>limits Invitrogen Corporation's liability only to the cost of the product</u>. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. Invitrogen reserves the right to select the method(s) used to analyze a product unless Invitrogen agrees to a specified method in writing prior to acceptance of the order.

Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore Invitrogen makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, please report it to our Technical Service Representatives.

Invitrogen assumes no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.

Purchaser Notification

Introduction

Use of the pGeneBLAzer[™] TOPO[®] TA Expression Kits is covered under the licenses detailed below.

Limited Use Label License No. 118: TOPO[®] Cloning Products

The TOPO[®] Cloning Technology products and their use are the subject of one or more of U.S. Patent Nos. 5,766,891, 6,548,277 and/or other pending U.S. and foreign patent applications licensed to Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Purchaser Notification, continued

Limited Use Label License No. 120: TA[®] Cloning Products The TA® Cloning Technology products and their use are the subject of one or more of U.S. Patent Nos. 5,487,993, and 5,827,657, and/or pending foreign patent applications owned by Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Purchaser Notification, continued

Limited Use Label License No. 150: GeneBLAzer[™] Technology

This product and/or its use is the subject of one or more of U.S. Patent Nos. 5,741,657, 5,955,604, 6,291,162, and 6,472,205 and foreign equivalents owned by and/or licensed to Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The right to use this product for internal research specifically excludes the right to use this product to identify, discover, and profile compounds that act as a flavor, fragrance or tasteenhancers and modify a target identified in taste, olfaction, or pheromone detection, provided the compound does not require FDA approval of an NDA for claims of safety and efficacy. The right to use methods claimed in the foregoing patents with this product for research purposes can only be acquired by the use of GeneBLAzer® substrates purchased from Invitrogen Corporation or its authorized distributors. The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to an academic collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use, or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Purchaser Notification, continued

Limited Use Label License No. 152: TR40 This product and/or its use is the subject of one or more of U.S. Patent Nos. 6,200,762, 6,214,563, and 6,221,612 owned by and/or licensed to Invitrogen Corporation. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use, or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Product Qualification

Introduction	The pGeneBLAzer [™] TOPO [®] TA Expression Kits are qualified as described below.
Vectors	The pGeneBLAzer [™] (parental vector of pGeneBLAzer-TOPO [®]) and pGeneBLAzer [™] /UbC plasmids are qualified by restriction analysis. The pGeneBLAzer [™] vector is qualified by restriction digest prior to adaptation with topoisomerase I. Restriction digests must demonstrate the correct banding pattern when electrophoresed on an agarose gel.
TOPO [®] Cloning Efficiency	Once adapted with topoisomerase I, the pGeneBLAzer ^{TM} vector is lot-qualified using the control reagents included in the kit. Under conditions described on pages 20-22, a 750 bp control PCR product is TOPO [®] Cloned into pGeneBLAzer-TOPO [®] and subsequently transformed into the One Shot [®] TOP10 chemically competent <i>E. coli</i> included with the kit.
	Each lot of vector should yield greater than 85% cloning efficiency.
Primers	Primers are lot-qualified by DNA sequencing experiments using the dideoxy chain termination technique.
One Shot [®] TOP10 Chemically Competent <i>E. coli</i>	All competent cells are tested for transformation efficiency using the control plasmid included in the One Shot [®] kit. Transformed cultures are plated on LB plates containing 100 μ g/ml ampicillin and the transformation efficiency is calculated. Test transformations are performed in duplicate. Transformation efficiency should be greater than 1 x 10 ⁹ cfu/ μ g plasmid DNA.
	In addition, untransformed cells are tested for the appropriate antibiotic sensitivity and lack of phage contamination.
GeneBLAzer [™] Detection Kits	For information about how the GeneBLAzer ^{M} In Vitro Detection Kit and the GeneBLAzer ^{M} In Vivo Detection Kit are qualified, refer to the GeneBLAzer ^{M} Detection Kits manual.

References

Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1994). Current Protocols in Molecular Biology (New York: Greene Publishing Associates and Wiley-Interscience).

Brownstein, M. J., Carpten, J. D., and Smith, J. R. (1996). Modulation of Non-Templated Nucleotide Addition by *Taq* DNA Polymerase: Primer Modifications that Facilitate Genotyping. BioTechniques 20, 1004-1010.

Chen, C., and Okayama, H. (1987). High-Efficiency Transformation of Mammalian Cells by Plasmid DNA. Mol. Cell. Biol. 7, 2745-2752.

Chu, G., Hayakawa, H., and Berg, P. (1987). Electroporation for the Efficient Transfection of Mammalian Cells with DNA. Nucleic Acids Res. *15*, 1311-1326.

Cole, C. N., and Stacy, T. P. (1985). Identification of Sequences in the Herpes Simplex Virus Thymidine Kinase Gene Required for Efficient Processing and Polyadenylation. Mol. Cell. Biol. *5*, 2104-2113.

Felgner, P. L., Holm, M., and Chan, H. (1989). Cationic Liposome Mediated Transfection. Proc. West. Pharmacol. Soc. 32, 115-121.

Felgner, P. L. a., and Ringold, G. M. (1989). Cationic Liposome-Mediated Transfection. Nature 337, 387-388.

Innis, M. A., Gelfand, D. H., Sninsky, J. J., and White, T. S. (1990) PCR Protocols: A Guide to Methods and Applications. Academic Press, San Diego, CA.

Nenoi, M., Mita, K., Ichimura, S., Cartwright, I. L., Takahashi, E., Yamaguchi, M., and Tsuji, H. (1996). Heterogeneous Structure of the Polyubiquitin Gene UbC of HeLa S3 Cells. Gene 175, 179-185.

Shigekawa, K., and Dower, W. J. (1988). Electroporation of Eukaryotes and Prokaryotes: A General Approach to the Introduction of Macromolecules into Cells. BioTechniques *6*, 742-751.

Shuman, S. (1994). Novel Approach to Molecular Cloning and Polynucleotide Synthesis Using Vaccinia DNA Topoisomerase. J. Biol. Chem. 269, 32678-32684.

Shuman, S. (1991). Recombination Mediated by Vaccinia Virus DNA Topoisomerase I in *Escherichia coli* is Sequence Specific. Proc. Natl. Acad. Sci. USA *88*, 10104-10108.

Southern, P. J., and Berg, P. (1982). Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter. J. Molec. Appl. Gen. 1, 327-339.

Sutcliffe, J. G. (1978). Nucleotide Sequence of the Ampicillin Resistance Gene of *Escherichia coli* Plasmid pBR322. Proc. Nat. Acad. Sci. USA *75*, 3737-3741.

Wigler, M., Silverstein, S., Lee, L.-S., Pellicer, A., Cheng, Y.-C., and Axel, R. (1977). Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. Cell *11*, 223-232.

References, continued

Wulff, B. S., O'Hare, M. M., Boel, E., Theill, L. E., and Schwartz, T. W. (1990). Partial Processing of the Neuropeptide Y Precursor in Transfected CHO Cells. FEBS Lett. *261*, 101-105.

Zlokarnik, G., Negulescu, P. A., Knapp, T. E., Mere, L., Burres, N., Feng, L., Whitney, M., Roemer, K., and Tsien, R. Y. (1998). Quantitation of Transcription and Clonal Selection of Single Living Cells with b-Lactamase as Reporter. Science 279, 84-88.

©2003-2004 Invitrogen Corporation. All rights reserved.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.



United States Headquarters:

Invitrogen Corporation 1600 Faraday Avenue Carlsbad, California 92008 Tel: 1 760 603 7200 Tel (Toll Free): 1 800 955 6288 Fax: 1 760 603 7229 Email: tech_service@invitrogen.com

European Headquarters:

Invitrogen Ltd 3 Fountain Drive Inchinnan Business Park Paisley PA4 9RF, UK Tel (Free Phone Orders): 0800 269 210 Tel (General Enquiries): 0800 5345 5345 Fax: +44 (0) 141 814 6287 Email: eurotech@invitrogen.com

International Offices:

Argentina 5411 4556 0844 Australia 1 800 331 627 Austria 0800 20 1087 Belgium 0800 14894 Brazil 0800 11 0575 Canada 800 263 6236 China 10 6849 2578 Denmark 80 30 17 40

France 0800 23 20 79 Germany 0800 083 0902 Hong Kong 2407 8450 India 11 577 3282 Italy 02 98 22 201 Japan 03 3663 7974 The Netherlands 0800 099 3310 New Zealand 0800 600 200 Norway 00800 5456 5456

Spain & Portugal 900 181 461 Sweden 020 26 34 52 Switzerland 0800 848 800 Taiwan 2 2651 6156 UK 0800 838 380 For other countries see our website

www.invitrogen.com